Turtle Cameron — SEC Form 4 filings
SEC reporting owner CIK 1758363. 16 Form 4 filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-02-02 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 34 legs across 11 filings — 195,000 shares, $9,994,545 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
- Largest priced transaction: sale of 10,176 shares @ $87.44 ($889,789) in Spyre Therapeutics, Inc., filed 2026-07-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | Chief Executive Officer, Director | 14 | — | 34 legs · 195,000 sh · $9,994,545 | 3 |
| Damora Therapeutics, Inc. (DMRA) | Director | 1 | — | — | 1 |
| Oruka Therapeutics, Inc. (ORKA) | Director | 1 | — | — | 1 |
Form 4 filings — Turtle Cameron
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 2,500 @ $86.36 · Sale (S): 8,400 @ $87.15 · Sale (S): 3,700 @ $88.06 · Sale (S): 400 @ $89.07 | EDGAR |
| 2026-08-05 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 800 @ $93.97 · Sale (S): 7,157 @ $95.10 · Sale (S): 5,635 @ $95.93 · Sale (S): 1,392 @ $96.82 · Sale (S): 16 @ $97.46 | EDGAR |
| 2026-07-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 10,176 @ $87.44 · Sale (S): 4,234 @ $88.12 · Sale (S): 590 @ $88.91 | EDGAR |
| 2026-06-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 3,557 @ $69.40 · Sale (S): 8,149 @ $70.50 · Sale (S): 3,294 @ $71.38 | EDGAR |
| 2026-05-01 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 5,300 @ $69.54 · Sale (S): 3,600 @ $70.77 · Sale (S): 1,000 @ $71.76 · Sale (S): 3,100 @ $73.14 · Sale (S): 1,700 @ $74.23 · Sale (S): 300 @ $74.96 | EDGAR |
| 2026-04-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 12,344 @ $49.20 · Sale (S): 2,656 @ $49.92 | EDGAR |
| 2026-03-25 | 4 | Damora Therapeutics, Inc. (DMRA) | Grant/award (A): 37,313 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 5,900 @ $41.73 · Sale (S): 9,100 @ $42.49 | EDGAR |
| 2026-02-04 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 957 @ $31.82 · Sale (S): 14,043 @ $32.87 | EDGAR |
| 2026-01-13 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 528,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 12,709 @ $30.47 · Sale (S): 2,191 @ $31.79 · Sale (S): 100 @ $32.39 | EDGAR |
| 2025-12-03 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 10,995 @ $28.73 · Sale (S): 4,005 @ $29.83 | EDGAR |
| 2025-11-05 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 28,155 @ $23.13 · Sale (S): 16,845 @ $23.66 | EDGAR |
| 2025-06-03 | 4 | Oruka Therapeutics, Inc. (ORKA) | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 400 @ $9.82 | EDGAR |
| 2024-02-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 277,750 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1758363 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →